InvestSMART

Vitrafy Life Sciences Limited (ASX: VFY) - Share Price

- Current share price for VFY : $3.800

Vitrafy Life Sciences Limited (VFY) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It has developed cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets (>88% recovery vs >50% industry standard), cell & gene therapies (96% viability vs 70% industry minimum), aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain software platform, and Smart Packaging systems.

VFY General Information +

ASX Code VFY
Website N/A
Industry/Sector Life Sciences Tools & Services
Market Cap ($M) 236
VFY Share Price $3.800
Day High $4.170
Day Low $3.800
Last Close $3.800
VFY Share Price Movement - ( No change )
Prices as at 16:40, 24 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Vitrafy Life Sciences Limited (VFY) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Vitrafy Life Sciences Limited (VFY) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Vitrafy Life Sciences Limited (VFY) price-sensitive announcements

VFY - FY26 Full Year Results Presentation
In the fiscal year 2026, Vitrafy Life Sciences Limited achieved significant milestones acr
Vitrafy Life Sciences Limited (VFY)
4 Aug 2026 | 8:23 AM
VFY - FY26 Appendix 4E and Annual Report
Vitrafy Life Sciences Limited released its FY26 Appendix 4E and Annual Report detailing it
Vitrafy Life Sciences Limited (VFY)
4 Aug 2026 | 8:22 AM
VFY - Q4 FY26 Quarterly Activities Report and Appendix 4C
Vitrafy Life Sciences Limited reported significant progress in Q4 FY26, including a $32 mi
Vitrafy Life Sciences Limited (VFY)
29 Jul 2026 | 8:29 AM
VFY - Vitrafy enters a partnership with Hoxworth Blood Center
Vitrafy Life Sciences Limited has entered into a strategic partnership with Hoxworth Blood
Vitrafy Life Sciences Limited (VFY)
23 Jul 2026 | 8:29 AM

Vitrafy Life Sciences Limited (VFY) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
Health Care $237 FY26 Corporate Governance Statement 4 Aug 2026 8:23AM $3.700 $3.800 risen by 2.70%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
Health Care $237 FY26 Appendix 4G 4 Aug 2026 8:23AM $3.700 $3.800 risen by 2.70%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
Health Care $237 FY26 Full Year Results Presentation 4 Aug 2026 8:23AM $3.700 $3.800 risen by 2.70%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
Health Care $237 FY26 Appendix 4E and Annual Report 4 Aug 2026 8:22AM $3.700 $3.800 risen by 2.70%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
Health Care $237 Vitrafy FY26 Investor Briefing 3 Aug 2026 1:36PM $3.690 $3.800 risen by 2.98%
Vitrafy Life Sciences Limited (VFY)
ORDINARY FULLY PAID
Health Care $237 Q4 FY26 Quarterly Activities Report and Appendix 4C 29 Jul 2026 8:29AM $3.090 $3.800 risen by 22.98%

VFY Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2026A -$16.17 -$25.20 -65.50% 0.00 0.00 0.00% 0.0%
2025A -$32.71 -$73.00 347.20% 0.00 0.00 0.00% 0.0%
2024A -$10.43 -$16.30 33.40% 0.00 0.00 0.00% 0.0%

VFY Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2024 A 2025 A 2026 A 2024 A 2025 A 2026 A 2024 A 2025 A 2026 A
Vitrafy Life Sciences Limited (VFY) $251M -0.6552 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

VFY Directors

Name Position Start Date
Mr Brent Michael Leslie Owens Chief Executive Officer, Managing Director 29 Mar 2018
Ms Kathryn(Kate) Marian Munnings Non-Executive Director 10 Oct 2024
Mr Vaughan Webber Non-Executive Director 30 Nov 2022
Dr Jeannie(Jeannette) Joughin Non-Executive Director 20 Jan 2026
Dr Leigh Bernard Farrell Non-Executive Director, Non-Executive Chairman 16 Oct 2025

Vitrafy Life Sciences Limited (VFY) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
9 Jul 2026 WEBBER, Vaughan Buy Indirect Shares 2,454 $2.600 $6,380.400
9 Jul 2026 OWENS, Brent Buy Indirect Shares 1,636 $2.600 $4,253.600
9 Jul 2026 MUNNINGS, Kathryn(Kate) Buy Indirect Shares 2,454 $2.600 $6,380.400

See all changes in directors' interest & trades for Vitrafy Life Sciences Limited (VFY) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

VFY Management

Name Position
Simon Martin Chief Financial Officer
Michael Sapountzis Company Secretary

VFY Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Vitrafy Life Sciences Limited (VFY). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
4,825,839 (7.56%) Ryder Capital Limted and associated entities

VFY Calendar of Events

Date Event
03 August 2027 Report (Annual)
03 August 2027 Report (Prelim)
03 February 2027 Report (Interim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.